1
|
Perlikowska R, Silva J, Alves C, Susano P, Zakłos-Szyda M, Skibska A, Adamska-Bartłomiejczyk A, Wtorek K, do Rego JC, do Rego JL, Kluczyk A, Pedrosa R. Neuroprotective and Anti-inflammatory Effects of Rubiscolin-6 Analogs with Proline Surrogates in Position 2. Neurochem Res 2024; 49:895-918. [PMID: 38117448 PMCID: PMC10901950 DOI: 10.1007/s11064-023-04070-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 09/27/2023] [Accepted: 11/16/2023] [Indexed: 12/21/2023]
Abstract
Naturally occurring peptides, such as rubiscolins derived from spinach leaves, have been shown to possess some interesting activities. They exerted central effects, such as antinociception, memory consolidation and anxiolytic-like activity. The fact that rubiscolins are potent even when given orally makes them very promising drug candidates. The present work tested whether rubiscolin-6 (R-6, Tyr-Pro-Leu-Asp-Leu-Phe) analogs have neuroprotective and anti-inflammatory effects. These hypotheses were tested in the 6-hydroxydopamine (6-OHDA) injury model of human neuroblastoma SH-SY5Y and lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. The determination of reactive oxygen species (ROS), mitochondrial membrane potential (MMP), Caspase-3 activity, lipid peroxidation and nitric oxide (NO) production allowed us to determine the effects of peptides on hallmarks related to Parkinson's Disease (PD) and inflammation. Additionally, we investigated the impact of R-6 analogs on serine-threonine kinase (also known as protein kinase B, AKT) and mammalian target of rapamycin (mTOR) activation. The treatment with analogs 3 (Tyr-Inp-Leu-Asp-Leu-Phe-OH), 5 (Dmt-Inp-Leu-Asp-Leu-Phe-OH) and 7 (Tyr-Inp-Leu-Asp-Leu-Phe-NH2) most effectively prevented neuronal death via attenuation of ROS, mitochondrial dysfunction and Caspase-3 activity. Peptides 5 and 7 significantly increased the protein expression of the phosphorylated-AKT (p-AKT) and phosphorylated-mTOR (p-mTOR). Additionally, selected analogs could also ameliorate LPS-mediated inflammation in macrophages via inhibition of intracellular generation of ROS and NO production. Our findings suggest that R-6 analogs exert protective effects, possibly related to an anti-oxidation mechanism in in vitro model of PD. The data shows that the most potent peptides can inhibit 6-OHDA injury by activating the PI3-K/AKT/mTOR pathway, thus playing a neuroprotective role and may provide a rational and robust approach in the design of new therapeutics or even functional foods.
Collapse
Affiliation(s)
- Renata Perlikowska
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland.
| | - Joana Silva
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, Politécnico de Leiria, 2520-630, Peniche, Portugal
| | - Celso Alves
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, ESTM, Politécnico de Leiria, 2520-614, Peniche, Portugal
| | - Patricia Susano
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, Politécnico de Leiria, 2520-630, Peniche, Portugal
| | - Małgorzata Zakłos-Szyda
- Institute of Molecular and Industrial Biotechnology, Faculty of Biotechnology and Food Sciences, Lodz University of Technology, Stefanowskiego 2/22, 90-537, Lodz, Poland
| | - Agnieszka Skibska
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland
| | - Anna Adamska-Bartłomiejczyk
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland
| | - Karol Wtorek
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland
| | - Jean-Claude do Rego
- Platform of Behavioural Analysis (SCAC), Inserm US51 - CNRS UAR2026 HeRaCLes, Institute For Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Rouen, France
| | - Jean-Luc do Rego
- Platform of Behavioural Analysis (SCAC), Inserm US51 - CNRS UAR2026 HeRaCLes, Institute For Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Rouen, France
| | - Alicja Kluczyk
- Faculty of Chemistry, University of Wroclaw, 50-383, Wroclaw, Poland
| | - Rui Pedrosa
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, ESTM, Politécnico de Leiria, 2520-614, Peniche, Portugal
| |
Collapse
|
2
|
Kijewska M, Wołczański G, Kosson P, Wieczorek R, Lisowski M, Stefanowicz P. Stapling of leu-enkephalin analogs with bifunctional reagents for prolonged analgesic activity. Chem Commun (Camb) 2024; 60:3023-3026. [PMID: 38356394 DOI: 10.1039/d3cc06345c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2024]
Abstract
The design and synthesis of leu-enkephalin analogs by replacing the glycine residues with N-(2-thioethyl)glycines and opening the cyclisation potential is presented. The cyclization (stapling) was achieved using bifunctional reagents (hexafluorobenzene and trithiocyanuric acid derivatives). The CD conformational studies of the stapled analogs suggest that the peptides adopt the type I β-turn conformation, which is in agreement with the theoretical analysis. The analog containing a trithiocyanuric acid derivative with a benzyl substituent shows potent analgesic activity.
Collapse
Affiliation(s)
- Monika Kijewska
- Faculty of Chemistry, University of Wrocław, Joliot-Curie 14, 50-383 Wrocław, Poland.
| | - Grzegorz Wołczański
- Faculty of Chemistry, University of Wrocław, Joliot-Curie 14, 50-383 Wrocław, Poland.
| | - Piotr Kosson
- Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinskiego Street, 02-106 Warszawa, Poland
| | - Robert Wieczorek
- Faculty of Chemistry, University of Wrocław, Joliot-Curie 14, 50-383 Wrocław, Poland.
| | - Marek Lisowski
- Faculty of Chemistry, University of Wrocław, Joliot-Curie 14, 50-383 Wrocław, Poland.
| | - Piotr Stefanowicz
- Faculty of Chemistry, University of Wrocław, Joliot-Curie 14, 50-383 Wrocław, Poland.
| |
Collapse
|
3
|
Zhang Q, Xu B, Chen D, Wu S, Hu X, Zhang X, Yu B, Zhang S, Yang Z, Zhang M, Fang Q. Structure-Activity Relationships of a Novel Cyclic Hexapeptide That Exhibits Multifunctional Opioid Agonism and Produces Potent Antinociceptive Activity. J Med Chem 2024; 67:272-288. [PMID: 38118143 DOI: 10.1021/acs.jmedchem.3c01347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2023]
Abstract
The cyclic peptide c[d-Lys2, Asp5]-DN-9 has recently been identified as a multifunctional opioid/neuropeptide FF receptor agonist, displaying potent analgesic activity with reduced side effects. This study utilized Tyr-c[d-Lys-Gly-Phe-Asp]-d-Pro-NH2 (0), a cyclic hexapeptide derived from the opioid pharmacophore of c[d-Lys2, Asp5]-DN-9, as a chemical template. We designed, synthesized, and characterized 22 analogs of 0 with a single amino acid substitution to investigate its structure-activity relationship. Most of these cyclic hexapeptide analogs exhibited multifunctional activity at μ and δ opioid receptors (MOR and DOR, respectively) and produced antinociceptive effects following subcutaneous administration. The lead compound analog 15 showed potent agonistic activities at the MOR, κ opioid receptor (KOR), and DOR in vitro and produced a strong and long-lasting analgesic effect through peripheral MOR and KOR in the tail-flick test. Further biological evaluation identified that analog 15 did not cause significant side effects such as tolerance, withdrawal, or reward liability.
Collapse
Affiliation(s)
- Qinqin Zhang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Biao Xu
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Dan Chen
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Shuyuan Wu
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Xuanran Hu
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Xiaodi Zhang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Bowen Yu
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Shichao Zhang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Zhenyun Yang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Mengna Zhang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Quan Fang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| |
Collapse
|
4
|
Zhang M, Xu B, Li N, Zhang Q, Chen D, Wu S, Yu B, Zhang X, Hu X, Zhang S, Jing Y, Yang Z, Jiang J, Fang Q. All-Hydrocarbon Stapled Peptide Multifunctional Agonists at Opioid and Neuropeptide FF Receptors: Highly Potent, Long-Lasting Brain Permeant Analgesics with Diminished Side Effects. J Med Chem 2023; 66:17138-17154. [PMID: 38095323 DOI: 10.1021/acs.jmedchem.3c02093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2023]
Abstract
Our previous study reported the multifunctional agonist for opioid and neuropeptide FF receptors DN-9, along with its cyclic peptide analogues c[D-Cys2, Cys5]-DN-9 and c[D-Lys2, Asp5]-DN-9. These analogues demonstrated potent antinociceptive effects with reduced opioid-related side effects. To develop more stable and effective analgesics, we designed, synthesized, and evaluated seven hydrocarbon-stapled cyclic peptides based on DN-9. In vitro calcium mobilization assays revealed that most of the stapled peptides, except 3, displayed multifunctional agonistic activities at opioid and neuropeptide FF receptors. Subcutaneous administration of all stapled peptides resulted in effective and long-lasting antinociceptive activities lasting up to 360 min. Among these stapled peptides, 1a and 1b emerged as the optimized compounds, producing potent central antinociception following subcutaneous, intracerebroventricular, and oral administrations. Additionally, subcutaneous administration of 1a and 1b caused nontolerance antinociception, with limited occurrence of constipation and addiction. Furthermore, 1a was selected as the final optimized compound due to its wider safety window compared to 1b.
Collapse
Affiliation(s)
- Mengna Zhang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Biao Xu
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Ning Li
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Qinqin Zhang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Dan Chen
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Shuyuan Wu
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Bowen Yu
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Xiaodi Zhang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Xuanran Hu
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Shichao Zhang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Yuhong Jing
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Zhenyun Yang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| | - Jinhong Jiang
- Jiangsu Province Key Laboratory of Anesthesiology, Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology, NMPA Key Laboratory for Research and Evaluation of Narcotic and Psychotropic Drugs, Xuzhou Medical University, 209 Tongshan Rd, Xuzhou, Jiangsu 221004, China
| | - Quan Fang
- Institute of Physiology, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China
| |
Collapse
|
5
|
Lee YS. Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery. Biomolecules 2022; 12:biom12091241. [PMID: 36139079 PMCID: PMC9496382 DOI: 10.3390/biom12091241] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Revised: 08/29/2022] [Accepted: 09/02/2022] [Indexed: 11/16/2022] Open
Abstract
Despite various advantages, opioid peptides have been limited in their therapeutic uses due to the main drawbacks in metabolic stability, blood-brain barrier permeability, and bioavailability. Therefore, extensive studies have focused on overcoming the problems and optimizing the therapeutic potential. Currently, numerous peptide-based drugs are being marketed thanks to new synthetic strategies for optimizing metabolism and alternative routes of administration. This tutorial review briefly introduces the history and role of natural opioid peptides and highlights the key findings on their structure-activity relationships for the opioid receptors. It discusses details on opioid peptidomimetics applied to develop therapeutic candidates for the treatment of pain from the pharmacological and structural points of view. The main focus is the current status of various mimetic tools and the successful applications summarized in tables and figures.
Collapse
Affiliation(s)
- Yeon Sun Lee
- Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA
| |
Collapse
|
6
|
Balalaie S, Malakoutikhah M, Teixidó M, Fathi Vavsari V, Giralt E, Haghighatnia Y, Hamdan F, Arabanian A. Efficient Synthesis of Norbuprenorphines Coupled with Enkephalins and Investigation of Their Permeability. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH : IJPR 2020; 18:1277-1287. [PMID: 32641938 PMCID: PMC6934973 DOI: 10.22037/ijpr.2019.14712.12602] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
An efficient approach for the synthesis of norbuprenorphin derivatives through coupling of enkephalins and norbuprenorphine intermediates is described. Norbuprenorphine derivative was synthesized from thebaine and then, its reaction with succinic acid and phthalic acid was also studied. Meanwhile, the synthesis of enkephalins was done using solid phase peptide synthesis approach. Furthermore, after cleavage of the peptide from the surface of the resin, the coupling of enkephalins with norbuprenorphine derivative was done using TBTU as a coupling reagent then the derivatives were purified using preparative high-pressure liquid chromatography and their structures were confirmed using high-resolution mass spectrometry data. Later, their permeability across membranes was investigated. After PAMPA studies, it was found that the permeability of all norbuprenorphin-enkephalin derivatives was increased; however, succinic and phthalic acid derivatives showed higher permeability than norbuprenorphine-Leu-enkephalin.
Collapse
Affiliation(s)
- Saeed Balalaie
- Peptide Chemistry Research Center, K. N. Toosi University of Technology, Tehran, Iran.,Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Morteza Malakoutikhah
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Baldiri Reixac 10, 08028 Barcelona, Spain
| | - Meritxell Teixidó
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Baldiri Reixac 10, 08028 Barcelona, Spain
| | - Vaezeh Fathi Vavsari
- Peptide Chemistry Research Center, K. N. Toosi University of Technology, Tehran, Iran
| | - Ernest Giralt
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Baldiri Reixac 10, 08028 Barcelona, Spain
| | - Yaghoub Haghighatnia
- Peptide Chemistry Research Center, K. N. Toosi University of Technology, Tehran, Iran
| | - Fatima Hamdan
- Peptide Chemistry Research Center, K. N. Toosi University of Technology, Tehran, Iran
| | - Armin Arabanian
- Peptide Chemistry Research Center, K. N. Toosi University of Technology, Tehran, Iran
| |
Collapse
|
7
|
Xue H, Guo M, Wang C, Shen Y, Qi R, Wu Y, Xu Z, Chang M. Photo-induced preparation of unnatural α-amino acids: synthesis and characterization of novel Leu5-enkephalin analogues. Org Chem Front 2020. [DOI: 10.1039/d0qo00696c] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
2.6-Fold more long-lasting compared to Leu5-enkephalin.
Collapse
Affiliation(s)
- Hongxiang Xue
- Institute of Biochemistry and Molecular Biology
- School of Life Sciences
- Lanzhou University
- Lanzhou
- China
| | - Mengzhun Guo
- Institute of Drug Design & Synthesis
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province
- School of Basic Medical Science
- Lanzhou University
- Lanzhou
| | - Chao Wang
- Institute of Drug Design & Synthesis
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province
- School of Basic Medical Science
- Lanzhou University
- Lanzhou
| | - Yuxuan Shen
- Institute of Biochemistry and Molecular Biology
- School of Life Sciences
- Lanzhou University
- Lanzhou
- China
| | - Rupeng Qi
- Institute of Drug Design & Synthesis
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province
- School of Basic Medical Science
- Lanzhou University
- Lanzhou
| | - Yifei Wu
- Institute of Biochemistry and Molecular Biology
- School of Life Sciences
- Lanzhou University
- Lanzhou
- China
| | - Zhaoqing Xu
- Institute of Drug Design & Synthesis
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province
- School of Basic Medical Science
- Lanzhou University
- Lanzhou
| | - Min Chang
- Institute of Biochemistry and Molecular Biology
- School of Life Sciences
- Lanzhou University
- Lanzhou
- China
| |
Collapse
|
8
|
Emery MA, Eitan S. Members of the same pharmacological family are not alike: Different opioids, different consequences, hope for the opioid crisis? Prog Neuropsychopharmacol Biol Psychiatry 2019; 92:428-449. [PMID: 30790677 DOI: 10.1016/j.pnpbp.2019.02.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 02/15/2019] [Accepted: 02/15/2019] [Indexed: 01/14/2023]
Abstract
Pain management is the specialized medical practice of modulating pain perception and thus easing the suffering and improving the life quality of individuals suffering from painful conditions. Since this requires the modulation of the activity of endogenous systems involved in pain perception, and given the large role that the opioidergic system plays in pain perception, opioids are currently the most effective pain treatment available and are likely to remain relevant for the foreseeable future. This contributes to the rise in opioid use, misuse, and overdose death, which is currently characterized by public health officials in the United States as an epidemic. Historically, the majority of preclinical rodent studies were focused on morphine. This has resulted in our understanding of opioids in general being highly biased by our knowledge of morphine specifically. However, recent in vitro studies suggest that direct extrapolation of research findings from morphine to other opioids is likely to be flawed. Notably, these studies suggest that different opioid analgesics (opioid agonists) engage different downstream signaling effects within the cell, despite binding to and activating the same receptors. This recognition implies that, in contrast to the historical status quo, different opioids cannot be made equivalent by merely dose adjustment. Notably, even at equianalgesic doses, different opioids could result in different beneficial and risk outcomes. In order to foster further translational research regarding drug-specific differences among opioids, here we review basic research elucidating differences among opioids in pharmacokinetics, pharmacodynamics, their capacity for second messenger pathway activation, and their interactions with the immune system and the dopamine D2 receptors.
Collapse
Affiliation(s)
- Michael A Emery
- Behavioral and Cellular Neuroscience, Department of Psychological and Brain Sciences, Texas A&M University, 4235 TAMU, College Station, TX 77843, USA; Interdisciplinary Program in Neuroscience, Texas A&M Institute for Neuroscience (TAMIN), College Station, TX, USA
| | - Shoshana Eitan
- Behavioral and Cellular Neuroscience, Department of Psychological and Brain Sciences, Texas A&M University, 4235 TAMU, College Station, TX 77843, USA; Interdisciplinary Program in Neuroscience, Texas A&M Institute for Neuroscience (TAMIN), College Station, TX, USA.
| |
Collapse
|
9
|
Hruby VJ. Multivalent peptide and peptidomimetic ligands for the treatment of pain without toxicities and addiction. Peptides 2019; 116:63-67. [PMID: 31014958 DOI: 10.1016/j.peptides.2019.02.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Revised: 02/09/2019] [Accepted: 02/13/2019] [Indexed: 12/14/2022]
Abstract
The current opioid crisis has created a tragic problem in medicine and society. Pain is the most ubiquitous and costly disease in society and yet all of our "treatments" have toxicities, especially for prolonged use. However, there are several alternatives that have been discovered in the past fifteen years that have been demonstrated in animals to have none of the toxicities of current drugs. Many of the compounds are multivalent and have novel biological activity profiles. Unfortunately, none of these have been in clinical trials in humans, perhaps because they were discovered in academic laboratories. A review of these novel chemicals are given in this paper.
Collapse
MESH Headings
- Analgesics, Opioid/therapeutic use
- Animals
- Humans
- Ligands
- Opioid Peptides/chemistry
- Opioid Peptides/therapeutic use
- Pain/drug therapy
- Pain/pathology
- Pain Management
- Peptides/adverse effects
- Peptides/therapeutic use
- Peptidomimetics/adverse effects
- Peptidomimetics/therapeutic use
- Receptors, Opioid/chemistry
- Receptors, Opioid/therapeutic use
- Receptors, Opioid, delta/chemistry
- Receptors, Opioid, delta/genetics
- Receptors, Opioid, mu/chemistry
- Receptors, Opioid, mu/genetics
Collapse
Affiliation(s)
- Victor J Hruby
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ, 85721, USA
| |
Collapse
|
10
|
Wang ZL, Pan JX, Song JJ, Tang HH, Yu HP, Li XH, Li N, Zhang T, Zhang R, Zhang MN, Xu B, Fang Q, Wang R. Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities. J Med Chem 2016; 59:10198-10208. [PMID: 27798836 DOI: 10.1021/acs.jmedchem.6b01181] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Zi-Long Wang
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Jia-Xin Pan
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Jing-Jing Song
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Hong-Hai Tang
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Hong-Ping Yu
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Xu-Hui Li
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Ning Li
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Ting Zhang
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Run Zhang
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Meng-Na Zhang
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Biao Xu
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Quan Fang
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| | - Rui Wang
- Key Laboratory of Preclinical
Study for New Drugs of Gansu Province, and Institute of Physiology,
School of Basic Medical Sciences, Lanzhou University, 199 Donggang
West Road, Lanzhou, 730000, PR China
| |
Collapse
|
11
|
Nair P, Yamamoto T, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma SW, Vanderah TW, Lai J, Porreca F, Hruby VJ. Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities. Bioorg Med Chem Lett 2015; 25:3716-20. [PMID: 26212775 PMCID: PMC4642890 DOI: 10.1016/j.bmcl.2015.06.030] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Revised: 06/06/2015] [Accepted: 06/08/2015] [Indexed: 11/21/2022]
Abstract
Several bifunctional peptides were synthesized and characterized based on the pentapeptide-derived ligand NP30 (1: Tyr-DAla-Gly-Phe-Gly-Trp-O-[3',5'-Bzl(CF3)2]). Modification and truncation of amino acid residues were performed, and the tripeptide-derived ligand NP66 (11: Dmt-DAla-Trp-NH-[3',5'-(CF3)2-Bzl]) was obtained based on the overlapping pharmacophore concept. The Trp(3) residue of ligand 11 works as a message residue for both opioid and NK1 activities. The significance lies in the observation that the approach of appropriate truncation of peptide sequence could lead to a tripeptide-derived chimeric ligand with effective binding and functional activities for both mu and delta opioid and NK1 receptors with agonist activities at mu and delta opioid and antagonist activity at NK1 receptors, respectively.
Collapse
Affiliation(s)
- Padma Nair
- Department of Chemistry and Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, AZ 85721, USA
| | - Takashi Yamamoto
- Department of Chemistry and Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, AZ 85721, USA
| | - Scott Cowell
- Department of Chemistry and Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, AZ 85721, USA
| | - Vinod Kulkarni
- Department of Chemistry and Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, AZ 85721, USA
| | - Sharif Moye
- Department of Pharmacology, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
| | - Edita Navratilova
- Department of Pharmacology, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
| | - Peg Davis
- Department of Pharmacology, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
| | - Shou-Wu Ma
- Department of Pharmacology, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
| | - Todd W Vanderah
- Department of Pharmacology, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
| | - Josephine Lai
- Department of Pharmacology, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
| | - Frank Porreca
- Department of Pharmacology, University of Arizona, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
| | - Victor J Hruby
- Department of Chemistry and Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, AZ 85721, USA.
| |
Collapse
|
12
|
Rational Approach to the Design of Bioactive Peptidomimetics: Recent Developments in Opioid Agonist Peptides. STUDIES IN NATURAL PRODUCTS CHEMISTRY 2015. [DOI: 10.1016/b978-0-444-63462-7.00002-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
13
|
Mollica A, Carotenuto A, Novellino E, Limatola A, Costante R, Pinnen F, Stefanucci A, Pieretti S, Borsodi A, Samavati R, Zador F, Benyhe S, Davis P, Porreca F, Hruby VJ. Novel cyclic biphalin analogue with improved antinociceptive properties. ACS Med Chem Lett 2014; 5:1032-6. [PMID: 25221662 DOI: 10.1021/ml500241n] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2014] [Accepted: 07/14/2014] [Indexed: 11/28/2022] Open
Abstract
Two novel opioid analogues have been designed by substituting the native d-Ala residues in position 2,2' of biphalin with two residues of d-penicillamine or l-penicillamine and by forming a disulfide bond between the thiol groups. The so-obtained compound 9 containing d-penicillamines showed excellent μ/δ mixed receptor affinities (K i (δ) = 5.2 nM; K i (μ) = 1.9 nM), together with an efficacious capacity to trigger the second messenger and a very good in vivo antinociceptive activity, whereas product 10 was scarcely active. An explanation of the two different pharmacological behaviors of products 9 and 10 was found by studying their conformational properties.
Collapse
Affiliation(s)
- Adriano Mollica
- Dipartimento
di Farmacia, Università di Chieti-Pescara “G. d’Annunzio”, Via dei Vestini, 31, 66100 Chieti, Italy
| | - Alfonso Carotenuto
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, Via D. Montesano, 49, 80131 Naples, Italy
| | - Ettore Novellino
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, Via D. Montesano, 49, 80131 Naples, Italy
| | - Antonio Limatola
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, Via D. Montesano, 49, 80131 Naples, Italy
| | - Roberto Costante
- Dipartimento
di Farmacia, Università di Chieti-Pescara “G. d’Annunzio”, Via dei Vestini, 31, 66100 Chieti, Italy
| | - Francesco Pinnen
- Dipartimento
di Farmacia, Università di Chieti-Pescara “G. d’Annunzio”, Via dei Vestini, 31, 66100 Chieti, Italy
| | - Azzurra Stefanucci
- Dipartimento
di Chimica, Sapienza, Università di Roma, P.le A. Moro,
5, 00187 Rome, Italy
| | - Stefano Pieretti
- Department
of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanità, V.le Regina Elena 299, 00161 Rome, Italy
| | - Anna Borsodi
- Institute
of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, 6726 Szeged, Hungary
| | - Reza Samavati
- Institute
of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, 6726 Szeged, Hungary
| | - Ferenc Zador
- Institute
of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, 6726 Szeged, Hungary
| | - Sándor Benyhe
- Institute
of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, 6726 Szeged, Hungary
| | | | | | | |
Collapse
|
14
|
Kira A, Javkhlantugs N, Miyamori T, Sasaki Y, Eguchi M, Kawamura I, Ueda K, Naito A. Interaction of Extracellular Loop II of κ-Opioid Receptor (196–228) with Opioid Peptide Dynorphin in Membrane Environments as Revealed by Solid State Nuclear Magnetic Resonance, Quartz Crystal Microbalance and Molecular Dynamics Simulation. J Phys Chem B 2014; 118:9604-12. [DOI: 10.1021/jp505412j] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Atsushi Kira
- Graduate School
of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
| | - Namsrai Javkhlantugs
- Graduate School
of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
- Center for Nanoscience and Nanotechnology & School of Engineering and Applied Science, National University of Mongolia, Ulaanbaatar 14201, Mongolia
| | - Takenori Miyamori
- Graduate School
of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
| | - Yoshiyuki Sasaki
- Graduate School
of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
| | - Masayuki Eguchi
- Graduate School
of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
| | - Izuru Kawamura
- Graduate School
of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
| | - Kazuyoshi Ueda
- Graduate School
of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
| | - Akira Naito
- Graduate School
of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan
| |
Collapse
|
15
|
[Dmt(1)]DALDA analogues with enhanced μ opioid agonist potency and with a mixed μ/κ opioid activity profile. Bioorg Med Chem 2014; 22:2333-8. [PMID: 24602401 DOI: 10.1016/j.bmc.2014.02.011] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 01/22/2014] [Accepted: 02/03/2014] [Indexed: 11/23/2022]
Abstract
Analogues of [Dmt(1)]DALDA (H-Dmt-d-Arg-Phe-Lys-NH2; Dmt=2',6'-dimethyltyrosine), a potent μ opioid agonist peptide with mitochondria-targeted antioxidant activity, were prepared by replacing Phe(3) with various 2',6'-dialkylated Phe analogues, including 2',6'-dimethylphenylalanine (Dmp), 2',4',6'-trimethylphenylalanine (Tmp), 2'-isopropyl-6'-methylphenylalanine (Imp) and 2'-ethyl-6'-methylphenylalanine (Emp), or with the bulky amino acids 3'-(1-naphthyl)alanine (1-Nal), 3'-(2-naphthyl)alanine (2-Nal) or Trp. Several compounds showed significantly increased μ agonist potency, retained μ receptor selectivity and are of interest as drug candidates for neuropathic pain treatment. Surprisingly, the Dmp(3)-, Imp(3)-, Emp(3)- and 1-Nal(3)-containing analogues showed much increased κ receptor binding affinity and had mixed μ/κ properties. In these cases, molecular dynamics studies indicated conformational preorganization of the unbound peptide ligands due to rotational restriction around the C(β)C(γ) bond of the Xxx(3) residue, in correlation with the observed κ receptor binding enhancement. Compounds with a mixed μ/κ opioid activity profile are known to have therapeutic potential for treatment of cocaine abuse.
Collapse
|
16
|
Hruby VJ, Cai M. Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles. Annu Rev Pharmacol Toxicol 2013; 53:557-80. [PMID: 23294313 DOI: 10.1146/annurev-pharmtox-010510-100456] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Peptide hormones and neurotransmitters are of central importance in most aspects of intercellular communication and are involved in virtually all degenerative diseases. In this review, we discuss physicochemical approaches to the design of novel peptide and peptidomimetic agonists, antagonists, inverse agonists, and related compounds that have unique biological activity profiles, reduced toxic side effects, and, if desired, the ability to cross the blood-brain barrier. Designing ligands for specific biological and medical needs is emphasized, as is the close collaboration of chemists and biologists to maximize the chances for success. Special emphasis is placed on the use of conformational (ϕ-ψ space) and topographical (χ space) considerations in design.
Collapse
Affiliation(s)
- Victor J Hruby
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721, USA.
| | | |
Collapse
|
17
|
2',6'-dimethylphenylalanine: a useful aromatic amino Acid surrogate for tyr or phe residue in opioid peptides. INTERNATIONAL JOURNAL OF MEDICINAL CHEMISTRY 2012; 2012:498901. [PMID: 25954528 PMCID: PMC4412257 DOI: 10.1155/2012/498901] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/31/2012] [Revised: 03/15/2012] [Accepted: 03/18/2012] [Indexed: 11/17/2022]
Abstract
Two aromatic amino acids, Tyr(1) and Phe(3) or Phe(4), are important structural elements in opioid peptides because they interact with opioid receptors. The usefulness of an artificial amino acid residue 2',6'-dimethylphenylalanine (Dmp) was investigated as an aromatic amino acid surrogate for several opioid peptides, including enkephalin, dermorphin, deltorphin, endomorphin, dynorphin A, and nociceptin peptides. In most peptides, substitutions of Phe(3) by a Dmp residue produced analogs with improved receptor-binding affinity and selectivity, while the same substitution of Phe(4) induced markedly reduced receptor affinity and selectivity. Interestingly, replacement of Tyr(1) by Dmp produced analogs with unexpectedly high affinity or produced only a slight drop in receptor affinity and bioactivity for most peptides. Thus, Dmp is also a useful surrogate for the N-terminal Tyr residue in opioid peptides despite the lack of a phenolic hydroxyl group, which is considered necessary for opioid activity. The Dmp(1)-substituted analogs are superior to 2',6'-dimethyltyrosine (Dmt)(1)-substituted analogs for high receptor selectivity since the latter generally have poor receptor selectivity. Thus, Dmp is very useful as an aromatic amino acid surrogate in opioid peptides and may be useful for developing other novel peptide mimetics with high receptor specificity.
Collapse
|
18
|
Rabasso N, Fadel A. Synthesis of an Enkephalin Analogue Containing an α,α-Disubstituted Heterocyclic Aminophosphonic Acid. PHOSPHORUS SULFUR 2011. [DOI: 10.1080/10426507.2010.535398] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- Nicolas Rabasso
- a Laboratoire de Synthèse Organique et Méthodologie , ICMMO, Université Paris-Sud , Orsay, France
| | - Antoine Fadel
- a Laboratoire de Synthèse Organique et Méthodologie , ICMMO, Université Paris-Sud , Orsay, France
| |
Collapse
|
19
|
Wu Z, Hruby VJ. Backbone alignment modeling of the structure-activity relationships of opioid ligands. J Chem Inf Model 2011; 51:1151-64. [PMID: 21488692 DOI: 10.1021/ci2000852] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Opioid studies are an important area of modern medicinal chemistry research. In this study we have provided innovative considerations to some long-standing problems in opioid studies, specifically the opioid pharmacophore and the potential binding modes of opioid ligands. Based on a new peptide backbone-alignment concept that we have developed along with this study, we discuss a wide variety of opioid ligands with respect to their structure-activity relationships.
Collapse
Affiliation(s)
- Zhijun Wu
- ABC Resources , Plainsboro, New Jersey 08536, United States
| | | |
Collapse
|
20
|
Liu WX, Wang R. Endomorphins: potential roles and therapeutic indications in the development of opioid peptide analgesic drugs. Med Res Rev 2011; 32:536-80. [DOI: 10.1002/med.20222] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
| | - Rui Wang
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province; School of Basic Medical Sciences; Institute of Biochemistry and Molecular Biology; State Key Laboratory of Applied Organic Chemistry; Lanzhou University; Lanzhou China
| |
Collapse
|
21
|
New potent biphalin analogues containing p-fluoro-L-phenylalanine at the 4,4' positions and non-hydrazine linkers. Amino Acids 2010; 40:1503-11. [PMID: 20924622 DOI: 10.1007/s00726-010-0760-7] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2010] [Accepted: 09/21/2010] [Indexed: 10/19/2022]
Abstract
We report the synthesis and the biological evaluation of two new analogues of the potent dimeric opioid peptide biphalin. The performed modification is based on the replacement of two key structural elements of the native biphalin, namely: the hydrazine bridge which joins the two palindromic moieties and the phenylalanine residues at the 4,4' positions of the backbone. The new analogues 9 and 10 contain 1,2-phenylenediamine and piperazine, respectively, in place of the hydrazidic linker and p-fluoro-L-phenylalanine residues at 4 and 4' positions. Binding values are: Kμ(i)=0.51 nM and Kδ(i)=12.8 nM for compound 9, Kμ(i)=0.09 nM and Kδ(i)=0.11 nM for analogue 10.
Collapse
|
22
|
Yamamoto T, Nair P, Jacobsen NE, Kulkarni V, Davis P, Ma SW, Navratilova E, Yamamura HI, Vanderah TW, Porreca F, Lai J, Hruby VJ. Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines. J Med Chem 2010; 53:5491-501. [PMID: 20617791 DOI: 10.1021/jm100157m] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Neuropathic pain states and tolerance to opioids can result from system changes in the CNS, such as up-regulation of the NK1 receptor and substance P, lead to antiopioid effects in ascending or descending pain-signaling pathways. Bifunctional compounds, possessing both the NK1 antagonist pharmacophore and the opioid agonist pharmacophore with delta-selectivity, could counteract these system changes to have significant analgesic efficacy without undesirable side effects. As a result of the introduction of cyclic and topological constraints with penicillamines, 2 (Tyr-cyclo[d-Pen-Gly-Phe-Pen]-Pro-Leu-Trp-NH-[3',5'-(CF(3))(2)-Bzl]) was found as the best bifunctional compound with effective NK1 antagonist and potent opioid agonist activities, and 1400-fold delta-selectivity over the mu-receptor. The NMR structural analysis of 2 revealed that the relative positioning of the two connected pharmacophores as well as its cyclic and topological constraints might be responsible for its excellent bifunctional activities as well as its significant delta-opioid selectivity. Together with the observed high metabolic stability, 2 could be considered as a valuable research tool and possibly a promising candidate for a novel analgesic drug.
Collapse
Affiliation(s)
- Takashi Yamamoto
- Departments of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Davis MP. Opioid receptor targeting ligands for pain management: a review and update. Expert Opin Drug Discov 2010; 5:1007-22. [DOI: 10.1517/17460441.2010.511473] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
24
|
Gach K, do-Rego JC, Fichna J, Storr M, Delbro D, Toth G, Janecka A. Synthesis and biological evaluation of novel peripherally active morphiceptin analogs. Peptides 2010; 31:1617-24. [PMID: 20434497 DOI: 10.1016/j.peptides.2010.04.018] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2010] [Revised: 04/20/2010] [Accepted: 04/21/2010] [Indexed: 12/27/2022]
Abstract
Morphiceptin (Tyr-Pro-Phe-Pro-NH(2)), a tetrapeptide present in the enzymatic digest of bovine beta-casein, is a selective ligand of the mu-opioid receptor. In the present study, we describe the synthesis of a series of novel morphiceptin analogs modified in positions 1-3. Two of the obtained analogs, [Dmt(1), D-Ala(2), D-1-Nal(3)]morphiceptin and [Dmt(1), D-NMeAla(2), D-1-Nal(3)]morphiceptin (Dmt-2',6'-dimethyltyrosine and d-1-Nal-3-(1-naphthyl)-D-alanine)) displayed very high mu-receptor affinity, resistance to enzymatic degradation, and remarkable supraspinally mediated analgesia, as shown in the hot-plate test after intracerebroventricular but not intravenous administration, which indicated that they could not cross the blood-brain barrier. Therefore, these two analogs were further tested in vitro and in vivo towards their possible peripheral analgesic activity and inhibitory effect on gastrointestinal (GI) motility. We report that both peptides showed strong antinociceptive effect in the writhing test after intraperitoneal administration, inhibited smooth muscle contractility in vitro and GI motility in vivo. Taken together, these findings indicate that the novel morphiceptin analogs which induce peripheral, but not central antinociception, inhibit GI transit, and possess exceptional metabolic stability, may provide an interesting approach to the development of peripherally restricted agents for the treatment of GI motility disorders, such as diarrhea or diarrhea-predominant irritable bowel syndrome.
Collapse
MESH Headings
- Analgesics, Opioid/chemical synthesis
- Analgesics, Opioid/chemistry
- Analgesics, Opioid/metabolism
- Analgesics, Opioid/pharmacology
- Animals
- Antidiarrheals/chemical synthesis
- Antidiarrheals/chemistry
- Antidiarrheals/metabolism
- Antidiarrheals/pharmacology
- Colon/drug effects
- Colon/metabolism
- Drug Design
- Drug Stability
- Endorphins/administration & dosage
- Endorphins/chemical synthesis
- Endorphins/chemistry
- Endorphins/metabolism
- Endorphins/pharmacology
- Female
- Gastrointestinal Motility/drug effects
- In Vitro Techniques
- Injections, Intraperitoneal
- Injections, Intraventricular
- Ligands
- Male
- Mice
- Mice, Inbred C57BL
- Muscle Contraction/drug effects
- Muscle, Smooth/drug effects
- Neurotransmitter Agents/chemical synthesis
- Neurotransmitter Agents/chemistry
- Neurotransmitter Agents/metabolism
- Neurotransmitter Agents/pharmacology
- Oligopeptides/chemical synthesis
- Oligopeptides/chemistry
- Oligopeptides/metabolism
- Oligopeptides/pharmacology
- Pain Measurement
- Peripheral Nerves/drug effects
- Peripheral Nervous System Agents/chemical synthesis
- Peripheral Nervous System Agents/chemistry
- Peripheral Nervous System Agents/metabolism
- Peripheral Nervous System Agents/pharmacology
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/antagonists & inhibitors
- Receptors, Opioid, mu/metabolism
- Structure-Activity Relationship
Collapse
Affiliation(s)
- Katarzyna Gach
- Department of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland
| | | | | | | | | | | | | |
Collapse
|
25
|
Wilczyńska D, Kosson P, Kwasiborska M, Ejchart A, Olma A. Synthesis and receptor binding of opioid peptide analogues containing beta3-homo-amino acids. J Pept Sci 2009; 15:777-82. [PMID: 19787815 DOI: 10.1002/psc.1175] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
beta-Amino acids containing hybrid peptides and beta-peptides show great potential as peptidomimetics. In this paper we describe the synthesis and affinity toward the micro- and delta-opioid receptors of beta-peptides, analogues of Leu-enkephalin, deltorphin I, dermorphin and alpha,beta-hybrides, analogues of deltorphin I. Substitution of alpha-amino acid residues with beta(3)-homo-amino acid residues, in general resulted in decrease of affinity to opioid receptors. However, the incorporation beta(3)h-D-Ala in position 2 or beta(3)hPhe in position 3 of deltorphin I resulted in potent and selective ligand for delta-opioid receptor. The NMR studies of beta-deltorphin I analogue suggest that conformational motions in the central part of the peptide backbone are partially restricted and some conformational preferences can be expected.
Collapse
Affiliation(s)
- Dominika Wilczyńska
- Institute of Organic Chemistry, Technical University of Łódź, Zeromskiego 116, 90-924 Łódź, Poland
| | | | | | | | | |
Collapse
|
26
|
Yamamoto T, Nair P, Ma SW, Davis P, Yamamura HI, Vanderah TW, Porreca F, Lai J, Hruby VJ. The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety. Bioorg Med Chem 2009; 17:7337-43. [PMID: 19762245 PMCID: PMC2775479 DOI: 10.1016/j.bmc.2009.08.035] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2009] [Revised: 08/14/2009] [Accepted: 08/18/2009] [Indexed: 11/30/2022]
Abstract
In order to improve metabolic stability, a ring structure with a cystine moiety was introduced into TY027 (Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-[3',5'-(CF(3))(2)Bzl]), which is a lead compound of our developing bifunctional peptide possessing opioid agonist and NK1 antagonist activities. TY038 (Tyr-cyclo[D-Cys-Gly-Phe-Met-Pro-D-Cys]-Trp-NH-[3',5'-(CF(3))(2)Bzl]) was found as a highly selective delta opioid agonist over mu receptor in conventional tissue-based assays, together with an effective NK1 antagonist activity and good metabolic stability with more than 24h half life in rat plasma.
Collapse
Affiliation(s)
- Takashi Yamamoto
- Department of Chemistry, University of Arizona, Tucson, AZ, 85721, USA
| | - Padma Nair
- Department of Chemistry, University of Arizona, Tucson, AZ, 85721, USA
| | - Shou-wu Ma
- Department of Pharmacology, University of Arizona, Tucson, AZ, 85721, USA
| | - Peg Davis
- Department of Pharmacology, University of Arizona, Tucson, AZ, 85721, USA
| | - Henry I. Yamamura
- Department of Pharmacology, University of Arizona, Tucson, AZ, 85721, USA
| | - Todd W. Vanderah
- Department of Pharmacology, University of Arizona, Tucson, AZ, 85721, USA
| | - Frank Porreca
- Department of Pharmacology, University of Arizona, Tucson, AZ, 85721, USA
| | - Josephine Lai
- Department of Pharmacology, University of Arizona, Tucson, AZ, 85721, USA
| | - Victor J. Hruby
- Department of Chemistry, University of Arizona, Tucson, AZ, 85721, USA
| |
Collapse
|
27
|
Josan JS, Morse DL, Xu L, Trissal M, Baggett B, Davis P, Vagner J, Gillies RJ, Hruby VJ. Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging. Org Lett 2009; 11:2479-82. [PMID: 19445485 DOI: 10.1021/ol900200k] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A general solid-phase synthetic strategy is developed to prepare fluorescent and/or lanthanide-labeled derivatives of the delta-opioid receptor (deltaOR) ligand H-Dmt-Tic-Lys(R)-OH. The high delta-OR affinity (K(i) = 3 nM) and desirable in vivo characteristics of the Cy5 derivative 1 suggest its usefulness for structure-function studies and receptor localization and as a high-contrast noninvasive molecular marker for live imaging ex vivo or in vivo.
Collapse
Affiliation(s)
- Jatinder S Josan
- Department of Chemistry, BIO5 Institute, The University of Arizona, Tucson, Arizona 85721, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
|
29
|
SCHMIDT RALF, WILKES BRIANC, CHUNG NGAN, LEMIEUX CAROLE, SCHILLER PETERW. Effect of aromatic amino acid substitutions in the 3-position of cyclic β-casomorphin analogues on μ-opioid agonist/δ-opioid antagonist properties*. ACTA ACUST UNITED AC 2009. [DOI: 10.1111/j.1399-3011.1996.tb00859.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
HORVAT Š, HORVAT J, VARGA-DEFTERDAROVIĆ L, PAVELIĆ K, CHUNG N, SCHILLER P. Methionine-enkephalin related glycoconjugates. ACTA ACUST UNITED AC 2009. [DOI: 10.1111/j.1399-3011.1993.tb00456.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Gentilucci L, Squassabia F, Demarco R, Artali R, Cardillo G, Tolomelli A, Spampinato S, Bedini A. Investigation of the interaction between the atypical agonist c[YpwFG] and MOR. FEBS J 2008; 275:2315-37. [DOI: 10.1111/j.1742-4658.2008.06386.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
32
|
Neuroprotection and functional recovery conferred by administration of kappa- and delta1-opioid agonists in a rat model of global ischemia. Physiol Behav 2008; 93:502-11. [DOI: 10.1016/j.physbeh.2007.10.015] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2007] [Revised: 10/10/2007] [Accepted: 10/16/2007] [Indexed: 11/21/2022]
|
33
|
Lee YS, Petrov R, Park CK, Ma SW, Davis P, Lai J, Porreca F, Vardanyan R, Hruby VJ. Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem 2007; 50:5528-32. [PMID: 17927164 DOI: 10.1021/jm061465o] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Enkephalin analogues with a 4-anilidopiperidine scaffold have been designed and synthesized to achieve therapeutic benefit for the treatment of pain due to mixed mu and delta opioid agonist activities. Ligand 16, in which a Dmt-substituted enkephalin-like structure was linked to the N-phenyl-N-piperidin-4-yl propionamide moiety, showed very high binding affinities (0.4 nM) at mu and delta receptors with an increased hydrophobicity (aLogP = 2.96). This novel lead compound was found to have very potent agonist activities in MVD (1.8 nM) and GPI (8.5 nM) assays.
Collapse
Affiliation(s)
- Yeon Sun Lee
- Department of Chemistry, University of Arizona, Tucson, Arizona 85721, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Caballero J, Saavedra M, Fernández M, González-Nilo FD. Quantitative structure-activity relationship of rubiscolin analogues as delta opioid peptides using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2007; 55:8101-4. [PMID: 17803260 DOI: 10.1021/jf071031h] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
Three-dimensional quantitative structure-activity relationship (3D-QSAR) studies were carried out on a series of 38 rubiscolins as delta opioid peptides using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). Quantitative information on structure-activity relationships is provided for further rational development and direction of selective synthesis. All models were carried out over a training set including 30 peptides. The best CoMFA model included electrostatic and steric fields and had a moderate Q (2) = 0.503. CoMSIA analysis surpassed the CoMFA results: the best CoMSIA model included only the hydrophobic field and had a Q (2) = 0.661. In addition, this model predicted adequately the peptides contained in the test set. Our model identified that the potency of delta opioid activity of rubiscolin analogues essentially exhibited a significant relationship with local hydrophobic and hydrophilic characteristics of amino acids at positions 3, 4, 5, and 6.
Collapse
Affiliation(s)
- Julio Caballero
- Centro de Bioinformática y Simulación Molecular, Universidad de Talca, 2 Norte 685, Casilla 721, Talca, Chile.
| | | | | | | |
Collapse
|
35
|
Shiotani K, Li T, Miyazaki A, Tsuda Y, Yokoi T, Ambo A, Sasaki Y, Bryant SD, Lazarus LH, Okada Y. Design and synthesis of opioidmimetics containing 2',6'-dimethyl-L-tyrosine and a pyrazinone-ring platform. Bioorg Med Chem Lett 2007; 17:5768-71. [PMID: 17826995 PMCID: PMC2366109 DOI: 10.1016/j.bmcl.2007.08.058] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2007] [Revised: 08/16/2007] [Accepted: 08/24/2007] [Indexed: 11/28/2022]
Abstract
Twelve 2',6'-dimethyl-L-tyrosine (Dmt) analogues linked to a pyrazinone platform were synthesized as 3- or 6-[H-Dmt-NH(CH(2))(n)],3- or 6-R-2(1H)-pyrazinone (n=1-4). 3-[H-Dmt-NH-(CH(2))(4)]-6-beta-phenethyl-5-methyl-2(1H)-pyrazinone 11 bound to mu-opioid receptors with high affinity (K(i)mu=0.13 nM; K(i)delta/K(i)mu=447) with mu-agonism (GPI IC(50)=15.9 nM) and weak delta-antagonism (MVD pA(2)=6.35). Key factors affecting opioid affinity and functional bioactivity are the length of the aminoalkyl chain linked to Dmt and the nature of the R residue. These data present a simplified method for the formation of pyrazinone opioidmimetics and new lead compounds.
Collapse
Affiliation(s)
- Kimitaka Shiotani
- The Graduate School of Food and Medicinal Sciences, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Mollica A, Guardiani G, Davis P, Ma SW, Porreca F, Lai J, Mannina L, Sobolev AP, Hruby VJ. Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem 2007; 50:3138-42. [PMID: 17539621 PMCID: PMC2274921 DOI: 10.1021/jm061048b] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Ring-closing metathesis has emerged as a powerful tool in organic synthesis for generating cyclic structures via C-C double bond formation. Recently, it has been successfully used in peptide chemistry for obtaining cyclic molecules bridged through an olefin unit in place of the usual disulfide bond. Here, we describe this approach for obtaining cyclic olefin bridged analogues of H-Tyr-c[D-Cys-Gly-Phe-Cys]-OH. The synthesis of the new ligands was performed using the second generation Grubbs' catalyst. The resulting cis-8 (cDADAE) and trans-9 (tDADAE) were fully characterized and tested at delta, mu, and kappa opioid receptors. Also the linear precursor 13 (lDADAE) and the hydrogenated derivative 11 (rDADAE) also were tested. All the cyclic products containing a olefinic bond are slightly selective but highly active and potent for the delta and mu opioid receptors. Activity toward the kappa opioid receptors was absent or very low.
Collapse
MESH Headings
- Allyl Compounds/chemical synthesis
- Allyl Compounds/chemistry
- Allyl Compounds/pharmacology
- Animals
- Enkephalins/chemical synthesis
- Enkephalins/chemistry
- Enkephalins/pharmacology
- Guinea Pigs
- Ileum/drug effects
- Ileum/innervation
- Ileum/physiology
- In Vitro Techniques
- Male
- Mice
- Mice, Inbred ICR
- Muscle Contraction/drug effects
- Muscle, Smooth/drug effects
- Muscle, Smooth/physiology
- Myenteric Plexus/physiology
- Peptides, Cyclic/chemical synthesis
- Peptides, Cyclic/chemistry
- Peptides, Cyclic/pharmacology
- Radioligand Assay
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, kappa/metabolism
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/metabolism
- Structure-Activity Relationship
- Vas Deferens/drug effects
- Vas Deferens/physiology
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Victor J. Hruby
- * To whom correspondence should be addressed. Tel.: +1 520 621 6332. Fax: +1 520 621 8407. E-mail:
| |
Collapse
|
37
|
Li T, Shiotani K, Miyazaki A, Tsuda Y, Ambo A, Sasaki Y, Jinsmaa Y, Marczak E, Bryant SD, Lazarus LH, Okada Y. Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands. J Med Chem 2007; 50:2753-66. [PMID: 17497839 PMCID: PMC2669435 DOI: 10.1021/jm061238m] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Endomorphin-2 (H-Tyr-Pro-Phe-Phe-NH2) and [Dmt1]EM-2 (Dmt = 2',6'-dimethyl-l-tyrosine) analogues, containing alkylated Phe3 derivatives, 2'-monomethyl (2, 2'), 3',5'- and 2',6'-dimethyl (3, 3', and 4', respectively), 2',4',6'-trimethyl (6, 6'), 2'-ethyl-6'-methyl (7, 7'), and 2'-isopropyl-6'-methyl (8, 8') groups or Dmt (5, 5'), had the following characteristics: (i) [Xaa3]EM-2 analogues exhibited improved mu- and delta-opioid receptor affinities. The latter, however, were inconsequential (Kidelta = 491-3451 nM). (ii) [Dmt1,Xaa3]EM-2 analogues enhanced mu- and delta-opioid receptor affinities (Kimu = 0.069-0.32 nM; Kidelta = 1.83-99.8 nM) without kappa-opioid receptor interaction. (iii) There were elevated mu-bioactivity (IC50 = 0.12-14.4 nM) and abolished delta-agonism (IC50 > 10 muM in 2', 3', 4', 5', 6'), although 4' and 6' demonstrated a potent mixed mu-agonism/delta-antagonism (for 4', IC50mu = 0.12 and pA2 = 8.15; for 6', IC50mu = 0.21 nM and pA2 = 9.05) and 7' was a dual mu-agonist/delta-agonist (IC50mu = 0.17 nM; IC50delta = 0.51 nM).
Collapse
MESH Headings
- Animals
- Binding, Competitive
- Brain/metabolism
- Guinea Pigs
- In Vitro Techniques
- Ligands
- Male
- Mice
- Muscle Contraction/drug effects
- Muscle, Smooth/drug effects
- Muscle, Smooth/innervation
- Muscle, Smooth/physiology
- Myenteric Plexus/physiology
- Neuromuscular Junction/drug effects
- Neuromuscular Junction/physiology
- Oligopeptides/chemical synthesis
- Oligopeptides/pharmacology
- Radioligand Assay
- Rats
- Rats, Sprague-Dawley
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/antagonists & inhibitors
- Receptors, Opioid, mu/agonists
- Structure-Activity Relationship
- Synaptosomes/metabolism
- Tyrosine/analogs & derivatives
- Tyrosine/chemical synthesis
- Tyrosine/pharmacology
- Vas Deferens/drug effects
- Vas Deferens/physiology
Collapse
Affiliation(s)
- Tingyou Li
- The Graduate School of Food and Medicinal Sciences, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan
| | - Kimitaka Shiotani
- The Graduate School of Food and Medicinal Sciences, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan
| | - Anna Miyazaki
- Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan
| | - Yuko Tsuda
- The Graduate School of Food and Medicinal Sciences, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan
- Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan
| | - Akihiro Ambo
- Department of Biochemistry, Tohoku Pharmaceutical University, Aoba-ku, Sendai 981-8558, Japan
| | - Yusuke Sasaki
- Department of Biochemistry, Tohoku Pharmaceutical University, Aoba-ku, Sendai 981-8558, Japan
| | - Yunden Jinsmaa
- Medicinal Chemistry Group, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, U.S.A
| | - Ewa Marczak
- Medicinal Chemistry Group, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, U.S.A
| | - Sharon D. Bryant
- Medicinal Chemistry Group, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, U.S.A
| | - Lawrence H. Lazarus
- Medicinal Chemistry Group, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, U.S.A
- Corresponding authors: Y. Okada: Tel: +81-78-974-1551, fax: +81-78-974-5689., E-mail: . L. H. Lazarus: Tel: +1-919-541-3238, fax: + 1-919-541-5737. E-mail:
| | - Yoshio Okada
- The Graduate School of Food and Medicinal Sciences, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan
- Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan
- Corresponding authors: Y. Okada: Tel: +81-78-974-1551, fax: +81-78-974-5689., E-mail: . L. H. Lazarus: Tel: +1-919-541-3238, fax: + 1-919-541-5737. E-mail:
| |
Collapse
|
38
|
Dolle RE, Michaut M, Martinez-Teipel B, Belanger S, Graczyk TM, DeHaven RN. Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett 2007; 17:2656-60. [PMID: 17350835 DOI: 10.1016/j.bmcl.2007.01.092] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2006] [Revised: 01/29/2007] [Accepted: 01/30/2007] [Indexed: 10/23/2022]
Abstract
A series of opioid peptide ligands containing modified N-terminal tyrosine (Tyr) residues was prepared and evaluated against cloned human mu, delta, and kappa opioid receptors. This work extends the recent discovery that (S)-4-carboxamidophenylalanine (Cpa) is an effective tyrosine bioisostere. Amino acids containing negatively charged functional groups in place of tyrosine's phenolic hydroxyl lacked receptor affinity, while exchange of Tyr for (S)-4-aminophenylalanine was modestly successful. Peptides containing the new amino acids, (S)-4-carboxamido-2,6-dimethylphenylalanine (Cdp) and (S)-beta-(2-aminobenzo[d]thiazol-6-yl)alanine (Aba), displayed binding (K(i)) and functional (EC(50)) profiles comparable to the parent ligands at the three receptors. Cdp represents the best performing Tyr surrogate in terms of overall activity, while Cpa and Aba show a subtle proclivity toward the delta receptor.
Collapse
MESH Headings
- Chemistry, Pharmaceutical/methods
- Cloning, Molecular
- Drug Design
- Humans
- Hydrogen Bonding
- Kinetics
- Ligands
- Models, Chemical
- Molecular Conformation
- Peptides/chemistry
- Receptors, Opioid/chemistry
- Receptors, Opioid, delta/chemistry
- Receptors, Opioid, kappa/chemistry
- Receptors, Opioid, mu/chemistry
- Tyrosine/chemistry
Collapse
Affiliation(s)
- Roland E Dolle
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | |
Collapse
|
39
|
Lee YS, Nyberg J, Moye S, Agnes RS, Davis P, Ma SW, Lai J, Porreca F, Vardanyan R, Hruby VJ. Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at mu and delta opioid receptors. Bioorg Med Chem Lett 2007; 17:2161-5. [PMID: 17329100 PMCID: PMC2274923 DOI: 10.1016/j.bmcl.2007.01.114] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2006] [Revised: 01/25/2007] [Accepted: 01/25/2007] [Indexed: 11/29/2022]
Abstract
New 4-anilidopiperidine analogues in which the phenethyl group of fentanyl was replaced by several aromatic ring-contained amino acids (or acids) were synthesized to study the biological effect of the substituents on mu and delta opioid receptor interactions. These analogues showed broad (47 nM-76 microM) but selective (up to 17-fold) binding affinities at the mu opioid receptor over the delta opioid receptor, as predicted from the message-address concept.
Collapse
Affiliation(s)
- Yeon Sun Lee
- Department of Chemistry, University of Arizona, Tucson, AZ 85721, USA
| | - Joel Nyberg
- Department of Chemistry, University of Arizona, Tucson, AZ 85721, USA
| | - Sharif Moye
- Department of Chemistry, University of Arizona, Tucson, AZ 85721, USA
| | - Richard S. Agnes
- Department of Chemistry, University of Arizona, Tucson, AZ 85721, USA
| | - Peg Davis
- Department of Pharmacology, University of Arizona, Tucson, AZ 85724, USA
| | - Shou-wu Ma
- Department of Pharmacology, University of Arizona, Tucson, AZ 85724, USA
| | - Josephine Lai
- Department of Pharmacology, University of Arizona, Tucson, AZ 85724, USA
| | - Frank Porreca
- Department of Pharmacology, University of Arizona, Tucson, AZ 85724, USA
| | - Ruben Vardanyan
- Department of Chemistry, University of Arizona, Tucson, AZ 85721, USA
| | - Victor J. Hruby
- Department of Pharmacology, University of Arizona, Tucson, AZ 85724, USA
- Corresponding author. Tel.: +1 520 621 6332; fax: +1 520 621 8407; e-mail:
| |
Collapse
|
40
|
Fichna J, do-Rego JC, Chung NN, Lemieux C, Schiller PW, Poels J, Broeck JV, Costentin J, Janecka A. Synthesis and Characterization of Potent and Selective μ-Opioid Receptor Antagonists, [Dmt, d-2-Nal4]endomorphin-1 (Antanal-1) and [Dmt1, d-2-Nal4]endomorphin-2 (Antanal-2). J Med Chem 2007; 50:512-20. [PMID: 17266203 DOI: 10.1021/jm060998u] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
To synthesize potent antagonists of the mu-opioid receptor, we prepared a series of endomorphin-1 and endomorphin-2 analogues with 3-(1-naphthyl)-d-alanine (d-1-Nal) or 3-(2-naphthyl)-d-alanine (d-2-Nal) in position 4. Some of these analogues displayed weak antagonist properties. We tried to strengthen these properties by introducing the structurally modified tyrosine residue 2,6-dimethyltyrosine (Dmt) in place of Tyr1. Among the synthesized compounds, [Dmt1, d-2-Nal4]endomorphin-1, designated antanal-1, and [Dmt1, d-2-Nal4]endomorphin-2, designated antanal-2, turned out to be highly potent and selective mu-opioid receptor antagonists, as judged on the basis of two functional assays, the receptor binding assay and the hot plate test of analgesia. Interestingly, another analogue of this series, [Dmt1, d-1-Nal4]endomorphin-1, turned out to be a moderately potent mixed mu-agonist/delta-antagonist.
Collapse
Affiliation(s)
- Jakub Fichna
- Laboratory of Biomolecular Chemistry, Institute of Biomedicinal Chemistry, Medical University, Lodz, Poland
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Polt R, Dhanasekaran M, Keyari CM. Glycosylated neuropeptides: a new vista for neuropsychopharmacology? Med Res Rev 2006; 25:557-85. [PMID: 16075406 DOI: 10.1002/med.20039] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The application of endogenous neuropeptides (e.g., enkephalins) as analgesics has been retarded by their poor stability in vivo and by their inability to effectively penetrate the blood-brain barrier (BBB). Effective BBB transport of glycosylated enkephalins has been demonstrated in several labs now. Analgesia (antinociception) levels greater than morphine, and with reduced side effects have been observed for several glycopeptides related to enkephalin. Somewhat paradoxically, enhanced BBB transport across this lipophilic barrier is achieved by attaching water-soluble carbohydrate groups to the peptide moieties to produce biousian glycopeptides that can be either water-soluble or membrane bound. Transport is believed to rely on an endocytotic mechanism (transcytosis), and allows for systemic delivery and transport of the water-soluble glycopeptides. Much larger endorphin/dynorphin glycopeptide analogs bearing amphipathic helix address regions also have been shown to penetrate the BBB in mice. This holds forth the possibility of transporting much larger neuropeptides across the BBB, which may encompass a wide variety of receptors beyond the opioid receptors.
Collapse
Affiliation(s)
- Robin Polt
- The Carl S. Marvel Laboratories, Department of Chemistry, The University of Arizona, Tucson, AZ 85721, USA
| | | | | |
Collapse
|
42
|
Recent advances in the Stevens rearrangement of ammonium ylides. Application to the synthesis of alkaloid natural products. Tetrahedron 2006. [DOI: 10.1016/j.tet.2005.09.123] [Citation(s) in RCA: 148] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
43
|
Abstract
Structure and function are intimately related. Nowhere is this more important than the area of bioactive molecules. It has been shown that the enantioselectivity of an enzyme is directly related to its chirality. X-ray crystallography is the only method for determining the "absolute" configuration of a molecule and is the most comprehensive technique available to determine the structure of any molecule at atomic resolution. Results from crystallographic studies provide unambiguous, accurate, and reliable 3-dimensional structural parameters, which are prerequisites for rational drug design and structure-based functional studies.
Collapse
Affiliation(s)
- Jeffrey R Deschamps
- Laboratory for the Structure of Matter, Naval Research Laboratory, Washington, DC 20375, USA.
| |
Collapse
|
44
|
Lung FDT, Chen CH, Liu JH. Development of highly potent and selective dynorphin A analogues as new medicines. ACTA ACUST UNITED AC 2005; 66:263-76. [PMID: 16218994 DOI: 10.1111/j.1399-3011.2005.00302.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Dynorphin A (Dyn A), a 17 amino acid peptide H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-OH, is a potent opioid peptide which interacts preferentially with kappa-opioid receptors. Research in the development of selective and potent opioid peptide ligands for the kappa-receptor is important in mediating analgesia. Several cyclic disulphide bridge-containing peptide analogues of Dyn A, which were conformationally constrained in the putative message or address segment of the opioid ligand, were designed, synthesized and assayed. To further investigate the conformational and topographical requirements for the residues in positions 5 and 11 of these analogues, a systematic series of Dyn A(1-11)-NH2 cyclic analogues incorporating the sulphydryl-containing amino acids L- and D-Cys and L- and D-Pen in positions 5 and 11 were synthesized and assayed. Cyclic lactam peptide analogues were also synthesized and assayed. Several of these cyclic analogues, retained the same affinity and selectivity (vs. the mu- and delta-receptors) as the parent Dyn A(1-11)-NH2 peptide in the guinea-pig brain (GPB), but exhibited a much lower activity in the guinea-pig ileum (GPI), thus leading to centrally vs. peripherally selective peptides. Studies of the structure-activity relationship of Dyn A peptide provide new insights into the importance of each amino acid residue (and their configurations) in Dyn A analogues for high potency and good selectivity at kappa-opioid receptors. We report herein the progress towards the development of Dyn A peptide ligands, which can act as agonists or antagonists at cell surface receptors that modulate cell function and animal behaviour using various approaches to rational peptide ligand-based drug design.
Collapse
Affiliation(s)
- F-D T Lung
- Department of Chemistry, Tunghai University, Taichung, Taiwan.
| | | | | |
Collapse
|
45
|
Gu X, Ying J, Agnes RS, Navratilova E, Davis P, Stahl G, Porreca F, Yamamura HI, Hruby VJ. Novel design of bicyclic beta-turn dipeptides on solid-phase supports and synthesis of [3.3.0]-Bicyclo([2,3])-leu-enkephalin analogues. Org Lett 2005; 6:3285-8. [PMID: 15355033 DOI: 10.1021/ol0488183] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
[structure: see text] External bicyclic beta-turn dipeptide mimetics provide an excellent design approach that can offer a rich chiral ensemble of structures with different backbone conformations. We report herein a novel design of a convergent combinatorial synthetic methodology, which is illustrated by the solid-phase synthesis of a series of [3.3.0]-bicyclo([2,3])-Leu-enkephalin analogues. The reactions were optimized and the epimeric configurations were determined by 2D NMR spectroscopy. Biological assays show that these analogues have more potent delta binding affinity and bioactivity for delta vs micro opioid receptor, which may be related to the different conformations preferred by these analogues in our modeling studies.
Collapse
Affiliation(s)
- Xuyuan Gu
- Department of Chemistry, University of Arizona, 1306 East University Boulevard, Tucson, Arizona 85721, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Gu X, Ying J, Min B, Cain JP, Davis P, Willey P, Navratilova E, Yamamura HI, Porreca F, Hruby VJ. Parallel synthesis and biological evaluation of different sizes of bicyclo[2,3]-Leu-enkephalin analogues. Biopolymers 2005; 80:151-63. [PMID: 15660379 DOI: 10.1002/bip.20208] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Parallel synthesis of peptides and peptidomimetics has been an important approach to search for biologically active ligands. A novel systematic synthesis of different size bicyclic dipeptide mimetics was developed on solid-phase supports. By taking advantage of the enantioselective synthesis of omega-unsaturated amino acids and their N-methylated derivatives, the hemiaminal problem was prevented in the pathway to thiazolidine formation. The bicyclic dipeptide was generated on the solid-phase support in three steps by an unconventional method. By inserting this bicyclic scaffold into the synthesis of a larger bioactive peptide, 11 different sizes of bicyclo[2,3]-Leu-enkephalin analogues were synthesized in a fast and efficient way. Modeling studies show that a reversed turn structure at positions 2-3 was favored when an L- and L-bicyclic scaffold was used, and that an extended conformation at the N-terminal was favored when a D- and L-bicyclic scaffold was inserted. Binding affinities and bioassay studies show ligands with micromolar binding affinities and antagonist bioactivities for the [6,5]- and [7,5]-bicyclo-Leu-enkephalin analogues.
Collapse
Affiliation(s)
- Xuyuan Gu
- Department of Chemistry, University of Arizona, Tucson, AZ 85721, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Bignan GC, Connolly PJ, Middleton SA. Recent advances towards the discovery of ORL-1 receptor agonists and antagonists. Expert Opin Ther Pat 2005. [DOI: 10.1517/13543776.15.4.357] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
48
|
Devanathan S, Salamon Z, Nagar A, Narang S, Schleich D, Darman P, Hruby V, Tollin G. Subpicomolar Sensing of δ-Opioid Receptor Ligands by Molecular-Imprinted Polymers Using Plasmon-Waveguide Resonance Spectroscopy. Anal Chem 2005; 77:2569-74. [PMID: 15828795 DOI: 10.1021/ac048476e] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Here we report, for the first time, the formation of a biomimetic covalently imprinted polymeric sensor for a target ligand, the delta-opioid G-protein coupled receptor agonist DPDPE, which reproducibly exhibits subpicomolar binding affinity in an aqueous environment. In addition to having a well-defined and homogeneous binding site, the imprinted polymer template is quite stable to storage in both the dry and wet states and has at least 6 orders of magnitude higher affinities than exhibited by similar peptide-based molecular-imprinted polymers (MIPs) thus far. A highly sensitive optical detection methodology, plasmon-waveguide resonance spectroscopy, was employed, capable of measuring binding in real time and discriminating between ligand molecules, without requiring labeling protocols (fluorophores or radioisotopes). The DPDPE-imprinted polymer showed a broad structure-activity relationship profile, not unlike that found for protein receptors. Such sensitivity and robustness of MIPs suggests potential applications ranging from biowarfare agent detection to pharmaceutical screening.
Collapse
Affiliation(s)
- Savitha Devanathan
- Department of Biochemistry and Molecular Biophysics, University of Arizona, Tucson, Arizona 85721, USA
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Hirose N, Murakawa K, Takada K, Oi Y, Suzuki T, Nagase H, Cools AR, Koshikawa N. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens. Neuroscience 2005; 135:213-25. [PMID: 16111831 DOI: 10.1016/j.neuroscience.2005.03.065] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2004] [Revised: 02/28/2005] [Accepted: 03/09/2005] [Indexed: 10/25/2022]
Abstract
The effect of interactions among mu- and delta-opioid receptors, especially the putative delta(1)- and delta(2)-opioid receptors, in the nucleus accumbens on accumbal dopamine release was investigated in awake rats by in vivo brain microdialysis. In agreement with previous studies, perfusion of the nucleus accumbens with the mu-, delta(1)- and delta(2)-opioid receptor agonists [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin (DAMGO), [D-Pen(2,5)]-enkephalin (DPDPE) and [D-Ser(2)]Leu-enkephalin-Thr(6), respectively, significantly enhanced the extracellular amount of accumbal dopamine in a dose-related manner (5.0 nmol and 50.0 nmol). However, the highest concentration tested (50.0 nmol) of DAMGO induced a biphasic effect, i.e. a rapid onset increase lasting for 75 min followed by a slower onset gradual and prolonged increase. The mu-opioid receptor antagonist D-Phe-Cys-Tyr-d-Trp-Orn-Thr-Phe-Thr-NH(2) (0.15 nmol) primarily reduced the DAMGO-induced second component. The delta(1)-opioid receptor antagonist (E)-7-benzylidenenaltrexone (0.15 nmol) significantly reduced the first component and abolished the second component induced by DAMGO, while the delta(2)-opioid receptor antagonist naltriben (1.5 nmol) significantly reduced only the first component. The DPDPE (50.0 nmol)-induced dopamine increase was almost completely abolished by (E)-7-benzylidenenaltrexone, but only partially reduced by D-Phe-Cys-Tyr-d-Trp-Orn-Thr-Phe-Thr-NH(2) and naltriben. The [D-Ser(2)]Leu-enkephalin-Thr(6) (50.0 nmol)-induced dopamine increase was almost completely abolished by naltriben, but not at all by D-Phe-Cys-Tyr-d-Trp-Orn-Thr-Phe-Thr-NH(2) and (E)-7-benzylidenenaltrexone. The non-selective opioid receptor antagonist naloxone (0.75 and 1.5 nmol) dose-dependently reduced the effects of DAMGO, DPDPE and [D-Ser(2)]Leu-enkephalin-Thr(6) but only to about 10-25% of the control values. Moreover, perfusion with the sodium channel blocker tetrodotoxin (0.1 nmol) reduced the DAMGO-induced dopamine increase by 75%, while it almost completely abolished the increase induced by DPDPE or [D-Ser(2)]Leu-enkephalin-Thr(6). The results show that stimulation of mu-opioid receptors or, to a lesser degree, delta(1)-opioid receptors results in a large naloxone-sensitive increase and a small naloxone-insensitive increase of extracellular dopamine. It is suggested that the naloxone-insensitive component is also tetrodotoxin-insensitive. Furthermore, it is hypothesized that stimulation of mu-opioid receptors activates delta(1)-receptors, which in turn activate delta(2)-opioid receptors, thereby giving rise to a rapid onset increase of extracellular dopamine. In addition, it is hypothesized that stimulation of another group of mu-opioid receptors activates a second group of delta(1)-opioid receptors that is not coupled to delta(2)-opioid receptors and mediates a slow onset increase of extracellular dopamine. Finally, it is suggested that stimulation of delta(1)- or delta(2)-opioid receptors inhibits mu-opioid receptors involved in the slow onset increase in extracellular dopamine, whereas stimulation of delta(1)-, but not delta(2)-, opioid receptors is suggested to activate mu-opioid receptors involved in the rapid increase in extracellular dopamine.
Collapse
MESH Headings
- Analgesics, Opioid/pharmacology
- Anesthetics, Local/pharmacology
- Animals
- Benzylidene Compounds/pharmacology
- Dopamine/metabolism
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-/pharmacology
- Enkephalin, D-Penicillamine (2,5)-/pharmacology
- Enkephalin, Leucine/analogs & derivatives
- Enkephalin, Leucine/pharmacology
- Extracellular Space/drug effects
- Extracellular Space/metabolism
- Male
- Microdialysis
- Naloxone/pharmacology
- Naltrexone/analogs & derivatives
- Naltrexone/pharmacology
- Narcotic Antagonists/pharmacology
- Nucleus Accumbens/drug effects
- Nucleus Accumbens/metabolism
- Rats
- Rats, Sprague-Dawley
- Receptors, Opioid, delta/drug effects
- Receptors, Opioid, delta/physiology
- Receptors, Opioid, mu/drug effects
- Receptors, Opioid, mu/physiology
- Somatostatin/analogs & derivatives
- Somatostatin/pharmacology
- Tetrodotoxin/pharmacology
Collapse
Affiliation(s)
- N Hirose
- Department of Dental Anaesthesiology, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo 101-8310, Japan
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Dolle RE, Machaut M, Martinez-Teipel B, Belanger S, Cassel JA, Stabley GJ, Graczyk TM, DeHaven RN. (4-Carboxamido)phenylalanine is a surrogate for tyrosine in opioid receptor peptide ligands. Bioorg Med Chem Lett 2004; 14:3545-8. [PMID: 15177470 DOI: 10.1016/j.bmcl.2004.04.039] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2004] [Revised: 04/12/2004] [Accepted: 04/12/2004] [Indexed: 11/20/2022]
Abstract
(S)-4-(Carboxamido)phenylalanine (Cpa) is examined as a bioisosteric replacement for the terminal tyrosine (Tyr) residue in a variety of known peptide ligands for the mu, delta and kappa opioid receptors. The Cpa-containing peptides, assayed against cloned human opioid receptors, display comparable binding affinity (Ki), and agonist potency (EC50) to the parent ligands at the three receptors. Cpa analogs of delta selective peptides show an increase in delta selectivity relative to the mu receptor. Cpa is the first example of an amino acid that acts as a surrogate for Tyr in opioid peptide ligands, challenging the long-standing belief that a phenolic residue is required for high affinity binding.
Collapse
MESH Headings
- Amino Acids, Aromatic/chemical synthesis
- Amino Acids, Aromatic/pharmacology
- Analgesics, Opioid/chemical synthesis
- Analgesics, Opioid/pharmacology
- Binding Sites
- Cell Line
- Humans
- Ligands
- Molecular Structure
- Opioid Peptides/metabolism
- Phenol/chemistry
- Phenylalanine/analogs & derivatives
- Phenylalanine/chemical synthesis
- Phenylalanine/pharmacology
- Receptors, Opioid, delta/drug effects
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, kappa/drug effects
- Receptors, Opioid, kappa/metabolism
- Receptors, Opioid, mu/drug effects
- Receptors, Opioid, mu/metabolism
- Tyrosine/pharmacology
Collapse
Affiliation(s)
- Roland E Dolle
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | | | | | |
Collapse
|